THE PREDICTIVE VALUE OF ANTI MULLERIAN HORMONE IN INTRAUTERINE INSEMINATION CYCLES

Many patients with ovulatory dysfunction or unexplained infertility proceed with intrauterine insemination (IUI) as first line fertility treatment. Ovarian reserve, especially as predicted by anti mullerian hormone (AMH), is often assessed at initial consultation, and the result used to help determine the treatment plan. While AMH has been well demonstrated to be a predictor of ovarian responsiveness to gonadotropins, it has not been validated as an independent marker of natural fertility or for outcomes in IUI cycles in the infertile population. Thus, our study investigated whether AMH levels are associated with ongoing pregnancy or clinical pregnancy loss in patients undergoing IUI cycles.